Brian O Mahony/X
Apr 26, 2026, 11:55
Brian O Mahony: Pierce Highlights Unique Inhibitor Cases in AAV-ET3 FVIII Gene Therapy Trial
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
”Pierce on Gene Therapy safety WFH Congress 2026 AAV-ET3 FVIII Human Porcine hybrid Gene Therapy trial in US.
Both participamts developed inhibitors.
These are the only inhibitors seen to date in all the haemophilia clinical trials.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention